01:08 , Feb 1, 2019 |  BC Week In Review  |  Company News

AZ, UPMC in value-based agreement for Brilinta

To reduce out-of-pocket costs for Medicare patients, AstraZeneca plc (LSE:AZN; NYSE:AZN) signed a value-based contract with UPMC Health Plan for Brilinta ticagrelor that links reimbursement of the drug to cardiovascular outcomes following a recent hospitalization...
22:22 , Jan 28, 2019 |  BC Extra  |  Company News

AZ, UPMC in value-based agreement for Brilinta

To reduce out-of-pocket costs for Medicare patients, AstraZeneca plc (LSE:AZN; NYSE:AZN) signed a value-based contract with UPMC Health Plan for Brilinta ticagrelor that links reimbursement of the drug to cardiovascular outcomes following a recent hospitalization...
18:36 , Nov 9, 2018 |  BC Week In Review  |  Company News

AZ looks to new medicines to drive growth

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Nov. 8 it will look to 10 new drugs to support a return to growth. The pharma reported 3Q18 product sales of $5.3 billion, up 9% at constant exchange rates...
23:40 , Nov 8, 2018 |  BC Extra  |  Company News

AZ looks to new medicines to drive growth

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Thursday it will look to 10 new drugs to support a return to growth. The pharma reported 3Q18 product sales of $5.3 billion, up 9% at constant exchange rates from...
18:14 , Oct 19, 2018 |  BC Week In Review  |  Financial News

PhaseBio, Osmotica price NASDAQ IPOs well below range

Cardiopulmonary company PhaseBio Pharmaceuticals Inc. (NASDAQ:PHAS) and neurology and women's health company Osmotica Pharmaceuticals plc (NASDAQ:OSMT) each priced IPOs well below their proposed ranges late Oct. 17. PhaseBio trading ended flat at $5 on Oct....
05:38 , Oct 18, 2018 |  BC Extra  |  Financial News

PhaseBio, Osmotica price IPOs well below range

Cardiopulmonary company PhaseBio Pharmaceuticals Inc. (NASDAQ:PHAS) and neurology and women's health company Osmotica Pharmaceuticals plc (NASDAQ:OSMT) each priced IPOs well below their proposed ranges late Wednesday. PhaseBio trading ended flat at $5 on Thursday, while...
20:31 , Oct 5, 2018 |  BC Week In Review  |  Clinical News

PhaseBio's PB2452 reverses antiplatelet activity of Brilinta in Phase I

PhaseBio Pharmaceuticals Inc. (Malvern, Pa.) said PB2452 (formerly MEDI2452) rapidly and completely reversed the antiplatelet activity of cardiovascular drug Brilinta ticagrelor from AstraZeneca plc (LSE:AZN; NYSE:AZN) in a Phase I trial. The company is developing...
18:42 , Sep 28, 2018 |  BC Week In Review  |  Financial News

PhaseBio files for $86.3M NASDAQ IPO

PhaseBio Pharmaceuticals Inc. (Malvern, Pa.) proposed on Sept. 21 to raise $86.3 million in an IPO on NASDAQ underwritten by Citigroup, Cowen, Stifel and Needham. On Sept. 7, PhaseBio raised $34 million in a series...
19:51 , Sep 7, 2018 |  BC Week In Review  |  Financial News

PhaseBio raises $34M series D

PhaseBio Pharmaceuticals Inc. (Malvern, Pa.) raised $34 million in a series D round from new investors Cormorant Asset Management, Rock Springs Capital and Mountain Group Partners. Existing investors New Enterprise Associates, Hatteras Venture Partners, AstraZeneca...
22:57 , Feb 2, 2018 |  BC Extra  |  Company News

AZ partners with Chinese internet giants, reports strong China sales

AstraZeneca plc (LSE:AZN; NYSE:AZN) announced two Chinese partnerships along with its 4Q17 earnings report Friday, which showed the company's sales in the country increased 30% at constant exchange rates to $813 million for the quarter....